Daraxonrasib (Rasonque): Chemical Identity and RAS Tri-Complex Mechanism

　　1.Chemical Identity

　　Daraxonrasib(development code RMC-6236,brand Rasonque)is an oral small-molecule anticancer agent with a complex scaffold containing multiple nitrogen heterocycles and sulfur-containing groups.

　　Key identifiers:

　　Formula:C₄₄H₅₈N₈O₅S

　　Molecular weight:~811.0 g/mol

　　CAS:2765081-21-6

　　PubChem CID:164726578

　　These parameters uniquely identify the compound and help distinguish generic name,development code,and different salt/crystal forms.

　　2.Not a Classic Direct RAS Binder

　　Unlike inhibitors that target a single inactive conformation or one mutation site,daraxonrasib works differently:

　　Inside the cell,it binds cyclophilin A(CypA)to form a drug–CypA binary complex.

　　This complex recognizes active,GTP-bound RAS.

　　Together they form a stable drug–CypA–RAS(ON)tri-complex.

　　Steric hindrance blocks RAS interaction with effector proteins such as RAF,suppressing MAPK proliferative signaling.

　　It is not limited to one mutation subtype and can engage multiple active KRAS,NRAS,and HRAS variants.

　　3.Why the Complex Structure Matters

　　The multi-heterocycle scaffold does not need high-affinity direct binding to RAS.Instead,it uses CypA to create a new binding interface—acting like a“molecular glue”that bridges CypA and active RAS.This expands druggability from a single mutation to broader RAS(ON)states.

　　4.How to Look Up the Structure

　　In PubChem or regulatory substance registries,you can view:

　　2D chemical structure;

　　formula and exact mass;

　　CAS,CID,InChIKey,and related identifiers.

　　Search using daraxonrasib,RMC-6236,or CAS 2765081-21-6 to avoid missing records due to brand-name or translation differences.